Sign in
TerminatedPhase 2

Digoxin In Treatment of Alcohol Associated Hepatitis

Key facts

Who runs it
Yale University
Where
New Haven, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 2
People taking part
23 people enrolled
Started
8 Oct 2021
Ended
12 Sept 2025
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Intravenous digoxin
Record updated
29 September 2026
Why it stopped
Slow accrual

Who can take part

Age
21 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Diagnosis of alcohol associated hepatitis based on clinical criteria or histologic evidence
  • Clinical criteria:; Onset of jaundice (bilirubin >3 mg/dL) within the prior 8 weeks; Regular alcohol use > 6 months, with intake of > 40 g/day (>280 g/week) for women; and > 60 g/day (>420 g/week) for men; AST > 50 IU/l; AST: ALT > 1.5 and both values < 400 IU/l
  • Histological evidence of alcohol associated hepatitis*; MDF >32 or MELD ≥ 20 to ≤ 35 on Day 0 of the trial; Age between 21 and 70 years, inclusive; In patients with possible alcohol associated hepatitis with confounding factors such as possible ischemic hepatitis, possible DILI, uncertain history of alcohol use, or atypical/abnormal laboratory tests (e.g., AST < 50 IU/IU/L or > 400 IU/IU/L, AST/ALT ratio < 1.5), antinuclearantibody > 1:160 or SMA > 1:80, standard of care liver biopsy may be performed as per discretion of the primary attending physician to confirm alcohol associated hepatitis and exclude competing etiologies. The decision to perform liver biopsy will be made by the primary team and will occur regardless of the study. As per current SOC, a liver biopsy may be obtained to confirm suspected alcohol-associated hepatitis and to rule out other potential etiologies of liver disease; If a liver biopsy is performed for clinically indicated reasons, we will store liver tissue that is left over after the portion needed for the primary indication has been identified

Who cannot take part

  • - Positive test for COVID-19 within 14 days prior to the screening visit
  • Sympathomimetics or ionotropic drugs (epinephrine, norepinephrine, dopamine, dobutamine, milrinone)
  • - Allergy or intolerance to digoxin
  • - Clinically active C. diff infection
  • - Acute hepatitis E, Cytomegalovirus, Epstein Barr Virus, Herpes Simplex Virus; 7- History of other liver diseases including hepatitis B (positive HBsAg or HBV DNA), hepatitis 8-C (positive HCV RNA), autoimmune hepatitis, Wilson disease, genetic hemochromatosis, alpha1-antitrypsin deficiency; 8-Diagnosis of Drug Induced Liver Injury (DILI), or other etiologies seen on liver imaging; 9 - History of HIV infection (positive HIV RNA or on treatment for HIV infection); 10 - Current diagnosis of cancer; 11- Renal failure defined by GFR <30 mL/min; 12 - Refractory ascites, defined as having more than 4 paracenteses in the preceding 8 weeks despite diuretic therapy; 13 - Prior exposure to experimental therapies or other clinical trial in last 3 months; 14 - Current acute or chronic pancreatitis; 15 - Active gastrointestinal bleeding unless resolved for >48 hours; 16 - Experiencing withdrawal seizures or considered at high risk for alcohol withdrawal seizures or delirium tremens; 17 - Heart rate less than 60 bpm at screening visit or at baseline; 18 - Current diagnosis of atrial fibrillation; 19 - Cardiomyopathy; 20 - Heart failure; 21 - Severe aortic valve disease; 22 - Presence of Accessory arterio-ventricular pathway (eg Wolf-Parkinson-White syndrome); 23 - Complete heart block or second degree arterio-ventricular block without pacemaker or implantable cardiac device; 24 - Any of the following within the previous 6 months: myocardial infarction, percutaneous intervention, pacemaker/implantable cardiac device implantation, cardiac surgery or stroke; 25 - Current use of the following medications:
  • Thyroid supplement (thyroid, levothyroxine sodium)
  • Calcium supplement
  • - Currently pregnant or breastfeeding
  • - Inability of patient, legally authorized representative or next-of-kin to provide informed consent
  • Antiarrhythmic (amiodarone, dofetilide, sotalol, dronedarone)
  • Parathyroid hormone analog (teriparatide)
  • Neuromuscular blocking agents (succinylcholine)
  • Ivabradine
  • Disulfiram

Where in United States

  • Yale New Haven Hospital, Yale School of MedicineNew Haven, United States

About the trial

What the trial wants to find out

Prospective, single center, open label, randomized controlled trial to explore whether digoxin treatment affects cytokine levels as biomarkers of inflammation in patients with acute alcohol associated hepatitis, digoxin administration and dose adjustment.

Read full original descriptionShow less

The study intervention will be intravenous digoxin (renal-based dosing for maximum of 28 days) versus no digoxin in an open-label 1:1 randomized allocation of patients with severe acute alcohol associated hepatitis.

The 2 groups in the trial

  • Arm A: DigoxinTreatment being tested

    In the digoxin arm, the intervention to be administered will be intravenous digoxin dosed by weight and by renal function using an adaption of the established FDA nomogram. Participants randomized to digoxin will receive an intravenous digoxin loading dose administered in 3 doses over 24 hours starting on Day 1. Digoxin levels will be monitored daily throughout the participant's hospital stay, to a maximum of 28 days. Digoxin will be discontinued at the time discharge if before 28 days.

    Treatment: Intravenous digoxin

  • Arm B: No DigoxinNo study treatment, for comparison

    In the no digoxin arm, no study drug or placebo will be administered.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Digoxin In Treatment of Alcohol Associated Hepatitis (DIGIT-AlcHep)
Record updated
29 September 2026